These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33592139)

  • 1. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
    Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
    Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.
    Bobbili P; Ryan K; Duh MS; Dua A; Fernandes AW; Pavilack M; Gomez JE
    Future Oncol; 2019 Oct; 15(29):3381-3393. PubMed ID: 31544510
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
    Martinez-Meehan D; Lutfi W; Dhupar R; Christie N; Baker N; Schuchert M; Luketich JD; Okusanya OT
    Clin Lung Cancer; 2020 Jul; 21(4):349-356. PubMed ID: 32299769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?
    Collaud S; Provost B; Besse B; Fabre D; Le Chevalier T; Mercier O; Mussot S; Fadel E
    J Surg Oncol; 2018 Jun; 117(7):1570-1574. PubMed ID: 29573419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
    Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
    Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.
    Grosu HB; Manzanera A; Shivakumar S; Sun S; Noguras Gonzalez G; Ost DE
    Lung Cancer; 2020 Feb; 140():55-58. PubMed ID: 31865279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
    Hansen RN; Zhang Y; Seal B; Ryan K; Yong C; Darilay A; Ramsey SD
    BMC Cancer; 2020 Apr; 20(1):276. PubMed ID: 32248816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
    She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W
    Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer.
    Kumar A; Srinivasan D; Potter AL; Mathey-Andrews C; Lanuti M; Martin LW; Jeffrey Yang CF
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1895-1905.e2. PubMed ID: 37722622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
    Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
    Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage III Non-small Cell Lung Cancer Management in England.
    Adizie JB; Khakwani A; Beckett P; Navani N; West D; Woolhouse I; Harden SV
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):688-696. PubMed ID: 31514942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
    Phernambucq EC; Hartemink KJ; Smit EF; Paul MA; Postmus PE; Comans EF; Senan S
    J Thorac Oncol; 2012 Aug; 7(8):1271-5. PubMed ID: 22659960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.